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Novelty statement 
The manuscript deals with the specific formulation approach (SMEDDS formulation) to 
improve systemic bioavailability of the poorly soluble model compound, and the employment 
of a comprehensive in vitro-in silico analysis to help identify the appropriate drug-specific 
formulation strategy. We believe that the results of this study may serve as a roadmap to 
define a proper formulation strategy for other poorly soluble drugs that undergo complex 
pharmacokinetics. 
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 In vitro/in silico approach in the development of simvastatin-loaded self-
microemulsifying drug delivery systems 
Objective: The aims of this study were to formulate simvastatin (SV)-loaded self-
microemulsifying drug delivery systems (SMEDDS), and explore the potential of these drug 
delivery systems to improve SV solubility, and also to identify the optimal place in the 
gastrointestinal (GI) tract for the release of SV using coupled in vitro/in silico approach. 
Significance: In comparison to other published results, this study considered the extensive 
presystemic clearance of SV, which could significantly decrease its systemic and hepatic 
bioavailability if SV is delivered into the small intestine. Methods: SV-loaded SMEDDS 
were formulated using various proportions of oils (PEG 300 oleic glycerides, propylene 
glycol monocaprylate, propylene glycol monolaurate), surfactant (PEG 400 caprylic/capric 
glycerides) and cosurfactant (polysorbate 80) and subjected to characterization, and 
physiologically-based pharmacokinetic (PBPK) modeling. Results: According to the in vitro 
results, the selected SMEDDS consisted of 10.0% PEG 300 oleic glycerides, 67.5% PEG 400 
caprylic/capric glycerides and 22.5% polysorbate 80. The use of acid-resistant capsules filled 
with SV-loaded SMEDDS was found helpful in protecting the drug against early degradation 
in proximal parts of the GI tract, however in silico simulations indicated that pH-controlled 
drug release system that dissolve in distal parts of the intestine might further improve SV 
bioavailability (up to 7.20%). Conclusions: The obtained results suggested that combined 
strategy for the improvement of SV bioavailability should comprise solubility enhancement 
and delayed drug release. The developed SV-specific PBPK model could potentially be used 
to assess the influence of formulation factors on drug absorption and disposition when 
developing SV oral dosage forms. 
Keywords: self-microemulsifying drug delivery systems (SMEDDS), simvastatin, poor 
solubility, absorption simulation, physiologically-based pharmacokinetic modeling  
Ac
ce
pt
d M
an
us
cri
pt
 Introduction 
 
Simvastatin (SV) is a cholesterol-lowering drug recognised for its potential to prevent 
cardiovascular diseases, since it treats hypercholesterolemia and can postpone the process of 
atherosclerosis [1]. SV is a lactone prodrug transformed into active form, β,δ-dihydroxyacid 
by nonspecific carboxyesterases in the intestinal wall, liver, and to some extent in plasma or 
by nonenzymatic hydrolysis [2]. Simvastatin acid (SVA) is responsible for lowering 
cholesterol levels through reversible and competitive inhibition of 3-hydroxy-3-
methylglytaril coenzyme A reductase, an enzyme involved in the biosynthesis of cholesterol 
in the liver [1]. In addition to their cholesterol-lowering properties, simvastatin exerts a 
number of pleiotropic (non-lipid-lowering) vasculoprotective actions primarily responsible 
for its anti-ischemic and anti-anginal properties, so some systemic availability is desired 
[3,4]. 
SV is a class II drug (low solubility, high permeability) according to the Biopharmaceutics 
classification system (BCS) [5]. Poor water solubility of SV combined with the extensive 
metabolism in the gut wall and liver (presystemic metabolism due to the affinity for CYP 
enzymes) results in a low systemic bioavailability (less than 5%) when the drug is 
administered in a conventional dosage form (e.g. immediate-release (IR) tablets) [6,7]. These 
considerations also apply for other poorly-soluble CYP3A4-substrate drugs. 
As one of the most promising formulation strategies, self-emulsifying drug delivery systems 
have been proposed to improve solubility and dissolution rate of SV [8-11]. The 
aforementioned approach is commonly used to resolve the issue of SV poor water solubility; 
however, none of the cited studies considered the extensive presystemic clearance of SV, 
which could in turn significantly decrease its systemic bioavailability if SV is delivered into 
the small intestine in a presolubilized form.  
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 Self-microemulsifying drug delivery systems (SMEDDS) are isotropic mixtures of drug, oil, 
surfactant, and cosurfactant, that under dilution in vivo can spontaneously form 
microemulsions with droplet size less than 50 nm [12]. These drug delivery systems allow a 
drug to remain in a dissolved state throughout its transit through the gastrointestinal (GI) 
tract, thus enhancing drug’s permeation across the intestinal membrane [13]. Therefore, for 
poorly water soluble drugs that exhibit dissolution rate-limited absorption (such as SV), 
SMEDDS can enhance the rate and extent of absorption, and offer an advantage over 
conventional oral dosage forms [12]. It is assumed that various factors may be responsible for 
the enhanced absorption of SMEDDS-formulated drugs, including improved drug 
solubilization, and/or increased membrane permeability and lymphatic transport, although the 
exact mechanisms are not fully elucidated [14,15]. With a large variety of excipients, ranging 
from oils to surfactants and cosurfactants, there are many different combinations that could 
form SMEDDS [16]. The abilities of the non-ionic polyglycolyzed glycerides including PEG 
300 oleic glycerides, PEG 400 caprylic/capric glycerides, propylene glycol monolaurate, and 
propylene glycol monocaprylate to formulate SMEDDS were widely investigated [8,9,17]. 
Due to their favourable properties, such as high solubilization capacity for poorly soluble 
drugs and low toxicity, these excipients have been increasingly used in SMEDDS [18].  
However, when considering formulation of SV-loaded SMEDDS, one should have in mind 
that presystemic metabolism of this drug can significantly lower its bioavailability in case a 
solubilized drug is delivered as an IR formulation. Some data suggest that modified-release 
formulations of statins might increase drug hepatic availability by minimizing drug release in 
proximal parts of the GI tract, and favouring drug uptake from ileum and colon [3]. 
Therefore, it is assumed that SV-loaded SMEDDS filled in acid-resistant capsules can 
postpone the absorption of the drug, and consequently improve its systemic and hepatic 
bioavailability. 
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 Recent trends in pharmaceutical development highlight the benefits of in silico 
physiologically-based pharmacokinetic (PBPK) modeling as a useful tool to estimate drug 
absorption and/or bioavailability, and thus facilitate the selection of appropriate formulation 
strategy, and development of novel oral drug delivery systems [19,20]. 
The aims of this study were (i) to develop and evaluate SMEDDS containing SV in order to 
explore their potential to improve drug solubility, and (ii) to predict the optimal place in the 
GI tract for the delivery of SV using coupled in vitro/in silico approach . In order to forecast 
pharmacokinetic (PK) behaviour of SV in humans, and provide mechanistic understanding of 
the processes the drug undergoes after oral administration of various types of oral SMEDDS 
formulations (immediate- and modified-release) PBPK modeling was used. In addition, the 
formulation approach applied in this study aimed to support the idea that the combined in 
vitro/in silico analysis should be embraced as an integral part of contemporary drug 
development. 
 
Materials and methods 
 
Materials 
Simvastatin (Ph. Eur. grade) was obtained from Hemofarm a.d. (Serbia). PEG 400 
caprylic/capric glycerides, propylene glycol monocaprylate, PEG 300 oleic glycerides, and 
propylene glycol monolaurate were obtained from Gattefossé (France). Polysorbate 80 was 
obtained from Sigma Aldrich Chemie GmbH (Germany). All other chemicals and reagents 
used were of analytical grade. 
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Methods 
Solubility studies 
Solubility of SV in oils (PEG 300 oleic glycerides, propylene glycol monocaprylate, 
propylene glycol monolaurate), surfactant (PEG 400 caprylic/capric glycerides) and 
cosurfactant (polysorbate 80) was determined by adding an excess amount of the drug to a 
screw-capped glass vials containing 2 ml of each excipient. The suspensions were shaken for 
48 h at room temperature (20 ± 2 °C) using IKA
®
 KS 260B shaker (IKA, Germany) at 350 
rpm, and then centrifuged for 30 min at 3000 rpm (MPW-56 centrifuge, MPW Med. 
Instruments, Poland). Aliquot of supernatant from each vial was diluted with ethanol 96% 
v/v, and drug content was quantified UV-spectrophotometrically (Evolution 300, Termo 
Fisher Scientific, England), since this method has been referenced in literature for 
quantification of SV [21,22]. Absorbance values were recorded at the wavelength of 
maximum absorption at 239 nm, and drug concentrations was calculated from the relevant 
calibration curve (r
2
 0.999). Specificity, linearity, accuracy, precision and sensitivity of the 
applied method was confirmed by in house validation (data not shown).  
Solubility studies were conducted in triplicate and the results are expressed as mean ± 
standard deviation (S.D.) to illustrate the dispersion in the obtained data. The results were 
statistically analyzed with one-way analysis of variance (ANOVA), using the p-value limit of 
0.05. In case of statistically significant differences within the obtained values (p ˂ 0.05), 
post-hoc Tukey test was used to estimate the difference within each pair of values. The 
difference between the two values was considered significant if the calculated Q value was 
larger than the critical Q value of the studentized range distribution (α = 0.05).. 
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Determination of microemulsion area 
Components of surfactant phase (surfactant (S) and cosurfactant (Cs)) were mixed in three 
different S/Cs ratios: 1:1, 2:1 and 3:1 (w/w). SMEDDS were prepared when the selected oil 
was added to surfactant phase at nine different ratios (9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8 and 
1:9, w/w). In order to observe the influence of drug on the microemulsion area, SV-loaded 
SMEDDS were prepared by adding the precise amount of SV (5% w/w) into the previously 
prepared SMEDDS and stirring on a magnetic stirrer (IKA
®
 RH basic 2, IKA, Germany) at 
50 ºC, until a clear solution was obtained. Each mixture was titrated with water in a dropwise 
manner while visually observed for transparency. During titration, samples were stirred on 
magnetic stirrer to allow equilibration. The “end point” was defined as the moment when 
clear mixtures turned turbid. Percentages of water, oil and surfactant phase, calculated at this 
point, were used to construct pseudoternary phase diagrams, and identify the microemulsion 
area in each diagram. The optimal formulations were selected at desired ratios of components 
based on the ability to form microemulsion. 
 
Droplet size determination 
The average droplet size and polydispersity index of unloaded and SV-loaded systems were 
determined immediately after dilution with purified water (1:10) by photon correlation 
spectroscopy (NanoZS90, Malvern Instruments, UK) at wavelength of 633 nm and a 
scattering angle of 90°. The results are presented as mean ± S.D. of three consecutive 
measurements for each sample. 
In order to evaluate the stability of the prepared samples average droplet size and 
polydispersity index were determined after three months, in the samples kept at room 
temperature (20 ± 2 ºC). 
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Drug content determination 
SV content was determined in freshly prepared samples and after 3-months storage (20 ± 2 
ºC). Accurately weighted SMEDDS samples (equivalent to 20 mg of SV) were dissolved in 
10 ml of ethanol 96%, sonicated for 10 min on ultrasonic bath (Bandelin Sonorex Super RK 
102H, Bandelin electronic, Germany) and diluted with ethanol 96% to determine drug 
content at 239 nm UV-spectrophotometrically. Experiments were run in triplicate and the 
results are expressed as a percent of label claim (mean ± S.D.). 
 
Dissolution studies 
The first set of experiments (setup I) comprised in vitro dissolution studies of SV-loaded 
SMEDDS (0.4 g of SMEDDS containing 20 mg SV) filled in hard gelatin capsules size “0”. 
The selected experimental setup I followed the USP requirements for determination of 
simvastatin release rate from simvastatin tablets (USP 35), with an adjustment that excluded 
the addition 0.5% SDS in dissolution medium, in order to provide more discriminative test 
conditions. Dissolution tests were carried out in a rotating basket apparatus (Erweka DT70, 
Germany) at 75 rpm, and 37 °C using 900 ml phosphate buffer pH 7.0 as dissolution medium. 
5 ml of samples were withdrawn at the predetermined time intervals (5, 10, 15, 30, 45, and 60 
min), and replaced with equal volume of phosphate buffer. All samples were filtered, and 
analyzed for SV content UV-spectrophotometrically at the wavelength of maximum 
absorption (239 nm). Analytical procedure was adapted from Chavhan et al. [23]. Dissolution 
experiments were run in triplicate, and data were expressed as mean value ± S.D. 
The obtained dissolution profiles (setup I) were compared using model-independent 
mathematical approach that includes calculation of the similarity factor (f2) between two 
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 profiles [24]. Drug release profiles are considered similar if f2 value ranges between 50 and 
100 [25]. 
In the second phase (setup II) 0.4 g the selected SV-loaded SMEDDS (containing 20 mg of 
SV) was filled into hypromellose (HPMC)-based acid-resistant capsules size “0” (DRcaps™ 
capsules, Capsugel, USA) and assayed for drug release using reciprocating cylinder apparatus 
(Bio-Dis Extended Release Tester, VanKel Technology Group, USA) under the “the media-
change” conditions depicted in Table 1. The proposed conditions were designed to simulate 
changes in physiological medium as the drug travels through GI tract under fasting 
conditions, because disintegration of acid-resistant capsules, and consequently drug release 
rate depend on media pH. At the predetermined time intervals (15, 30, 45, 60, 90, 120, 135, 
150, 180, 195, and 210 min), 5 ml of samples were collected and replaced with equal volume 
of dissolution medium. Determination of drug content followed the procedure applied in the 
setup I. The experiments were run in triplicate, and data were expressed as mean value ± S.D. 
 
Physiologically-based simulation of simvastatin pharmacokinetics 
GastroPlus™ software (version 9.0.0007, Simulations Plus, Inc., USA) was used to forecast 
SV pharmacokinetic properties following oral administration of different dosage forms. The 
software operates on the basis of the Advanced Compartmental Absorption and Transit 
(ACAT) of human GI tract that consists of nine compartments (stomach, duodenum, jejunum 
1 and 2, ileum 1-3, caecum and ascendent colon), and uses a system of mathematical 
equations to simulate the effect of physiological conditions on drug transit, dissolution, 
absorption and metabolism in the GI tract [26].  
The employed modeling approach consisted of two phases, whereas the first phase was model 
construction, followed by model exploration. The first phase referred to the selection of input 
data and evaluation of the simulation outcomes by comparison with the data from the in vivo 
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 study. Drug and formulation-related input parameters were experimentally determined, in 
silico estimated or taken from literature [Table 2]. Since the available human in vivo data 
referred to an IR tablet [2], drug dissolution rate under physiological conditions was predicted 
using Johnson dissolution model (based on modified Nernst-Bruner equation) [36]. All other 
ACAT model parameters were fixed at software default values that represent human 
fasted/fed physiology.  
In order to simulate drug disposition and metabolism in different tissues, ACAT model was 
linked to the whole-body PBPK model. The selected PBPK model used GastroPlus™ default 
physiology parameters for 30 years 70 kg American (Western) human adult, based on 
population mean values obtained from published data. Drug-specific model was constructed 
using metabolite tracking feature to simultaneously describe conversion and 
pharmacokinetics of SV and SVA, as depicted in Figure 1. 
Therefore, it accounted for the conversion of SV to SVA by intestinal and hepatic 
carboxylesterases (CES), and SV and SVA metabolism by CYP3A4 enzymes in the gut and 
liver. Michaelis constant (Km) and maximum reaction rate (Vmax) values for CES in the 
intestine and liver, and for CYP3A4 clearance of SV were taken from literature, as well as 
Km value for SVA metabolism by CYP3A4 [Table 2]. Vmax for CYP3A4 clearance of SVA 
was optimized to match the resultant SV and SVA pharmacokinetic profiles to the in vivo 
observed data [2]. CYP3A4 distribution factors for each gut compartment, and CYP3A4 
expression in the liver were provided within the program built-in database for the selected 
physiology (values calculated based on reported data [37]), and CES expression in the liver 
was calculated from literature data [38], assuming the software default concentration of  38 
mg microsomal protein/g liver. The drug was assumed to distribute freely across the 
membranes, meaning that the partition into the tissue is limited solely by the tissue blood 
flow rate. Thus all the tissues, except the liver, were treated as perfusion-limited. 
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 Tissue/plasma partition coefficients (Kp) for perfusion-limited tissues were calculated using a 
modified Rodgers-Single (Lukacova) equation, where unbound fraction in tissue (fut) was 
calculated using S+ equation [39]. In order to account for the OATP1B1-mediated transport 
of SVA across the basolateral hepatocytes membrane, the liver was set as a permeability-
limited tissue, and SV and SVA partition into the tissue was optimized. OATP1B1 expression 
in the liver was estimated from literature data [40], as well as the kinetic parameter Km [41], 
and Vmax was a fitted value [Table 2]. In addition to active uptake, passive diffusion of 
unbound SVA across the basolateral membrane was simulated by using permeability-surface 
area product (PStc) for the liver, calculated on the basis of SVA passive diffusion clearance 
of 4 μl/min/106 cells [30]. On the contrary, the PStc value for SV across the hepatic 
basolateral membrane was assumed to be 10000 times greater than the hepatic blood flow, to 
reflect perfusion- and not permeability-limited entry and exit of lipophilic SV to and from the 
liver intracellular compartment [30].  
The predictive power of the designed model was tested by comparing the simulation 
outcomes with digitized literature values on SV and SVA plasma concentration-time profiles 
following oral administration of a single 20 mg dose IR SV tablet [2]. Digital extraction of 
published data from the graph was performed using DigIt
TM
 program (version 1.0.4, 
Simulations Plus, Inc., USA). Since the participants in the reference study were given 
standard meals at 4 and 10 h after the drug administration, mixed multiple doses (MMD) 
option was used to switch from fasted to fed state, and accommodate food-induced changes 
in physiological parameters. 
In the model exploration phase, in vitro obtained SV dissolution profiles were used as inputs 
to describe drug release rate in vivo and simulate the expected PK outcomes following oral 
administration of the selected experimental formulations. Furthermore, virtual dissolution 
profile served as input to estimate the influence of hypothetical changes in formulation 
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 parameters (i.e. variations in drug release rate) on the drug PK profile. All other input 
parameters were kept at the same values as determined in the model construction phase.  
 
Results 
 
Characterization of SMEDDS 
Solubility of simvastatin 
Experimentally obtained solubilities of SV in various oils, surfactant, and cosurfactant are 
provided in Table 3. Solubility of SV in propylene glycol monocaprylate (115.18 ± 7.32 
mg/ml) was more than two times higher compared to drug’s solubility in PEG 300 oleic 
glycerides (53.34 ± 8.89 mg/ml). Overall, among the tested oils, SV exhibited the highest 
solubility in propylene glycol monocaprylate. The results of one-way ANOVA revealed 
statistically significant differences among the SV solubilities in different oils, since the 
calculated p-value was less than 0.05 (p-value = 0.019). In addition, post-hoc Tukey test 
indicated statistically significant difference between the SV solubilities in PEG 300 oleic 
glycerides and propylene glycol monocaprylate.  
 
Determination of microemulsion area 
The pseudoternary phase diagrams were constructed for unloaded SMEDDS [Figures 2-4] 
and SV-loaded SMEDDS [Figures 5-7] to identify microemulsion regions, and optimize the 
concentration of oil, surfactant and cosurfactant in SMEDDS. The areas of transparent 
systems are depicted as grey sequences. For both, unloaded and SV-loaded systems, it was 
evident that three diagrams with propylene glycol monolaurate as oil phase [Figures 2 and 5] 
had smaller microemulsion areas in comparison to the diagrams with other two oils, 
propylene glycol monocaprylate [Figures 3 and 6], and PEG 300 oleic glycerides [Figures 4 
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 and 7]. Unloaded SMEDDS with propylene glycol monocaprylate as oil phase produced 
larger microemulsion area [Figure 3] compared to those with PEG 300 oleic glycerides 
[Figure 4]. Also, there was a slight difference among propylene glycol monocaprylate-based 
systems with different ratios of surfactant and cosurfactant, since the systems with 1:1 and 
2:1 S/Cs ratios had slightly larger microemulsion area in contrast to systems with 3:1 S/Cs 
ratio [Figure 3]. 
It was observed that incorporation of SV (5% w/w) led to a decrease in the microemulsion 
areas in all diagrams [Figures 5-7]. There was a noticeable decrease in the microemulsion 
areas for SV-loaded SMEDDS with propylene glycol monocaprylate as oil phase [Figure 6] 
compared to those systems without SV [Figure 3]. SV-loaded systems with propylene glycol 
monocaprylate had smaller microemulsion area in comparison to SV-loaded systems with 
PEG 300 oleic glycerides [Figure 7]. 
The results of this study demonstrated that only four mixtures gave clear systems, when 
titrated with water, and can be regarded as SMEDDS. These systems [marked as F1-F4; 
Table 4] were selected for further investigation. 
 
Droplet size analysis 
The average droplet size and polydispersity index of both unloaded (F1-F4) and SV-loaded 
(F1s-F4s) SMEDDS are presented in Table 5. 
Unloaded SMEDDS (F1-F4), diluted immediately after preparation, had droplet size between 
10.25 nm and 18.58 nm. The average droplet size of SV-loaded SMEDDS, with PEG 300 
oleic glycerides as oil phase (F1s-F3s), was between 13.57 nm and 17.45 nm. However, it 
was observed that propylene glycol monocaprylate-based formulation (F4s) had larger 
droplet size (46.41 nm). 
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 As demonstrated in Table 5, the low values of polydispersity index (0.132 to 0.189) indicated 
good uniformity of droplet size of the unloaded SMEDDS. Furthermore, the obtained results 
showed that polydispersity index of F1s-F3s formulations determined after preparation 
indicated greater uniformity of droplet size, in comparison to formulation F4s whose 
polydispersity index > 0.2 implied larger variations of droplet size.  
Droplet size and polydispersity index determined after 3-month storage of the samples at 
room temperature revealed small changes of these values for SV-loaded formulations F1s-
F3s, which implies that these systems are considered to be stable. Therefore, taking into 
account that F4s formulation initially had larger droplet size and polydispersity index and 
was prone to greater changes due to storage, only samples F1s-F3s were selected as 
promising drug delivery systems. 
 
Drug content determination 
The average value for SV content in freshly prepared SMEDDS samples was 100.13 ± 
0.42%, which indicates that the applied preparation procedure and excipients did not affect 
the drug content. After 3-months storage, the determined drug content was 99.51 ± 0.67% 
demonstrating that no notable changes happened during this period.   
 
In vitro dissolution data 
Figure 8 shows comparative in vitro dissolution profiles of F1s-F3s formulations in hard 
gelatin capsules. In the first 5 min, more than 85% SV was released from F2s and F3s 
formulations. However, SV release from F1s formulation was lower compared to F2s and F3s 
formulations, reaching approximately 80% within the same time. Since drug release from F1s 
was somewhat slower than from formulations F2s and F3s, formulation F1 was excluded 
from further studies. The selection of the optimal formulation for additional investigation 
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 under the experimental setup II was based on the properties of the excipients. Namely, 
formulation F3s contained slightly higher percent of PEG 400 caprylic/capric glycerides 
[Table 4], known for its high tolerance, low toxicity in animals, and the ability to enhance the 
intestinal absorption of drugs [42-44], and therefore this formulation F3s was chosen for 
additional testing. 
The dissolution profile of the selected F3s formulation filled in acid-resistant capsules 
obtained under the setup II is shown in Figure 9. The acid-resistant capsules managed to 
sustain drug release in media pH 1.2 and pH 6.0, whereas at pH 6.4 the capsules started to 
disintegrate and gradually release the drug. Figure 9 also shows virtual dissolution profile 
(V1), generated to reflect the situation where 100% of the drug is dissolved in 180 min, 
which was later used in the in silico study to assess the influence of variations in drug release 
rate on the drug PK profile. 
  
In silico predictions 
The model-building strategy applied in this study focused on simulation of the key processes 
influencing SV pharmacokinetics, while keeping the model as simple as possible. Drug-
specific model was constructed based on the selected input parameters [Table 2], and 
population variability in the physiological and pharmacokinetic parameters was neglected, 
since the purpose of the in silico modeling was to estimate the influence of formulation 
factors on SV plasma exposure. Also, we need to note that the generated in silico results refer 
to a 70 kg human adult representative, but the designed model can be approximated to a wide 
range of body weights by adjusting the cardiac output and applying linear scaling to the tissue 
volumes and perfusion rates for the adjusted weight and cardiac output, respectively [45,46]. 
The predicted SV and SVA plasma concentration-time profiles are depicted in Figure 10, 
together with the corresponding values taken from literature [2]. Table 6 summarizes the 
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 predicted and in vivo observed SV/SVA PK parameters following oral administration of 20 
mg SV IR tablets. 
In order to assess the influence of formulation factors on the expected SV plasma profile, in 
vitro obtained dissolution profiles for F3s formulation filled in conventional hard gelatin 
capsules and acid-resistant capsules [Figures 11 and 12] were used as inputs in the designed 
SV-specific PBPK model. The simulated profiles are shown in Figure 11, and the generated 
PK parameters are depicted in Table 7. According to the obtained results, mere improvement 
in drug solubility, achieved by SV-loaded SMEDDS,  will not affect SV plasma exposure 
(0.97% difference in area-under-the-curve (AUC0→∞) in comparison to the value simulated 
based on software calculated drug dissolution). On the other hand, simulations based on drug 
dissolution from SMEDDS filled in acid-resistant capsules indicated certain increase in SV 
bioavailability (10.3% and 10.2% increase in bioavailability and AUC0→∞, respectively, in 
comparison to the values simulated based on software calculated drug dissolution) [Table 7].  
 
Discussion 
 
In contrast to SV poor water solubility (0.026 mg/ml experimentally determined), the drug 
displayed relatively high solubilities in the investigated excipients, which is in accordance 
with SV high log P value of 4.71 [31]. As depicted in Table 3, the experimental values were 
within or close to the wide range of values found in literature [8,9,11]. It was assumed that 
propylene glycol monocaprylate has greater capacity to solubilize poorly water soluble drugs 
due to certain polarity of caprylic acid, as discussed in the previous study with atorvastatin 
[47]. 
The selection of the most appropriate components for SMEDDS should be based on the 
constructed pseudoternary diagrams. One of the crucial factors that influence the formulation 
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 of SMEDDS is hydrophilic-lipophilic balance (HLB) value of the surfactant. Surfactants with 
HLB value 12-15, such as PEG 400 caprylic/capric glycerides and polysorbate 80 used in this 
study, are considered to have good efficacy for self-emulsification [48]. As pointed out in a 
previous study [49], the size of microemulsion area is determined by physical and chemical 
properties of the oil, aqueous and surfactant phases. Low surface tension at the oil–water 
interface, the presence of highly fluid interfacial film of surfactant, and penetration and 
association of oil molecules with interfacial surfactant film are prerequisites for the formation 
of microemulsion [49]. The presence of propylene glycol monolaurate as oil phase made the 
emulsification process more difficult compared to propylene glycol monocaprylate and PEG 
300 oleic glycerides, and consequently led to smaller microemulsion area in these diagrams. 
It has been reported that the drug incorporated in SMEDDS may have some effect on self-
emulsification performance of a system [13], which was confirmed by the results of this 
study. Namely, incorporation of SV (5% w/w) into the investigated SMEDDS led to decrease 
in the microemulsion region. This phenomena might be attributed to the incorporation of the 
drug into the oil droplets, resulting in the swelling of the oil droplets and expansion of the 
lipid phase, which signifies that higher ratio of surfactant phase is required in order to form 
SMEDDS [17,50]. Therefore, based on these results, only four systems [Table 4] were 
chosen as potential SMEDDS. 
Additional investigation of the formulated systems included droplet size analysis, which 
implied that all SV-loaded SMEDDS (F1s-F4s) formed microemulsions since the average 
droplet size was less than 50 nm [12]. However, drug loading had some impact on droplet 
size of propylene glycol monocaprylate-based formulation (F4s) in comparison to F1s-F3s 
formulations. These results revealed that the type of oil phase plays a vital role in the 
microemulsification process, as the sample prepared with propylene glycol monocaprylate as 
oil phase had significantly larger droplet size. 
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 After 3-month storage all unloaded SMEDDS showed similar results regarding droplet size 
and polydispersity index. In the case of SV-loaded SMEDDS, only PEG 300 oleic glycerides-
based formulations (F1s-F3s) could be regarded as stable after 3 months, which might be 
explained by the fact that PEG 300 oleic glycerides has higher HLB value (HLB=9) in 
comparison to propylene glycol monocaprylate (HLB=6), and good miscibility with PEG 400 
caprylic/capric glycerides as surfactant [50].  
The in vitro drug dissolution profiles from the selected formulations obtained under the 
experimental setup I were compared by calculating similarity factor. The calculated value f2 
53.55 for F2s and F3s formulations indicated that these dissolution profiles could be 
considered similar. However, comparison between F1s and F2s (f2 44.69) and between F1s 
and F3s (f2 36.65) showed that drug release profiles from these formulations were not similar, 
and that drug release from F1s was slower, which was one of the criteria to exclude this 
formulation from further studies (as indicated above).  
Under the experimental setup II, the acid-resistant capsules stayed intact in acidic buffer pH 
1.2, thus proving that the drug will not be released at low pH during the entire residence time 
in the stomach. The complete SV release occurred within 90 minutes in phosphate buffer 6.4. 
As already mentioned, design of SV oral dosage form with improved bioavailability requires 
a comprehensive analysis of formulation properties in conjunction with drug pharmacokinetic 
behaviour. SV undergoes a rather complex pharmacokinetics after oral administration, and 
the correct representation of the relevant PK properties in the in silico model is challenging. 
Several studies published in literature aimed to elucidate the underlying mechanisms that 
drive SV and SVA absorption, distribution and metabolism [30,31,51-53]. Nevertheless, 
substantial population variability in SV pharmacogenetics, namely polymorphisms in the 
genes encoding SV/SVA metabolizing enzymes and transporters [53-56], in addition to the 
variations in the reported values concerning drug-related biopharmaceutical properties, can 
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 be seen as a limitation for the accurate prediction of SV pharmacokinetics in a particular 
individual. Probably the most conceptual model that describes this drug pharmacokinetics is 
the recently published SV/SVA population model, developed by using an integrated 
population PBPK approach [30]. However, the complexity of this model, and the suggested 
modeling approach, might limit its wider application.  
In this study, in silico estimated 4.66% SV reaching the systemic circulation following intake 
of 20 mg SV IR tablets [Table 7] agreed well with the reported drug bioavailability of less 
than 5% [6,7]. The predicted maximum plasma concentration (Cmax) and AUC0→∞ for SV and 
SVA [Table 6] fitted into the range of values from the reference study [2]. The largest 
deviation from the in vivo data was noted for the time to reach SVA peak plasma levels (tmax), 
but this difference can be attributed to the large variability in the kinetics of SVA active 
uptake into the hepatocytes and concomitant metabolic clearance. Another annotation 
concerns a double peak phenomena in the mean plasma concentration profile observed in 
different in vivo studies [2,52,56]. Several hypothesis tried to explain these observations, 
including the influence of enterohepatic circulation, variable gastric emptying and intestinal 
transit time, site-specific absorption with different lag times and absorption rates, or irregular 
absorption process due to dynamically changing environment for drug dissolution in GI tract 
at each time of administration [2,52]. Although the designed model was not able to fully 
capture the second peak, simulation results using MMD option (visible "cusp" in the plasma 
profile corresponding to the meal time 4 h after drug administration [Figure 10]) indicate that 
intake of food might at least be partly responsible for the observed multiple peaks in SV 
plasma profiles. 
Simulation results based on input drug dissolution profiles indicated improved SV 
bioavailability with greater delay in drug release [Table 7], and the applied modeling 
approach provided a mechanistic explanation of the obtained data. Namely, in the case of SV-
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 loaded SMEDDS filled in hard gelatin capsules, small difference in AUC0→∞ in comparison 
to the value simulated based on software calculated dissolution is expected because large 
portion of the drug, absorbed from the GI tract, will undergo first pass extraction in the gut 
and liver. This outcome signifies that application of different techniques with the sole aim to 
improve SV solubility might not be the best strategy in the formulation of SV oral dosage 
forms. However, in the case of acid-resistant capsules, there was an expected delay in drug 
release and absorption [Figures 11 and 12]. In this case, in silico results indicated reduced SV 
hydrolysis and first pass extraction by CYP3A4, which is predominantly distributed in the 
upper small intestine. Consequently, the simulations showed that increased fraction of SV 
dose reached the portal vein followed by, to a lesser extent, increase in systemic drug 
exposure [Table 7]. Predictions based on virtual dissolution profile, generated to reflect the 
situation where 100% of the drug is dissolved in 180 min [Figure 9, profile V1], imply that 
further delay in drug release would additionally increase systemic drug bioavailability, up to 
7.20% [Table 7]. Any further increase in plasma drug exposure would be limited by extensive 
hepatic drug metabolism. Overall, the obtained results suggest that formulation of an oral 
dosage form that releases the drug in a presolubilized form in distal parts of the intestine 
might improve SV bioavailability for more than 50% in comparison to a conventional IR 
dosage form.  
 
Conclusion 
 
In this study, self-microemulsifying drug delivery system was developed for simvastatin, 
whereas the selected SMEDDS formulation consisted of 10% PEG 300 oleic glycerides, 
67.5% PEG 400 caprylic/capric glycerides and 22.5% polysorbate 80. Moreover, the 
outcomes of this study signify that application of different techniques with the sole aim to 
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 improve SV solubility is not the best strategy in the formulation of SV oral dosage forms 
because majority of the delivered dose would be cleared by presystemic metabolism in the 
small intestine. Instead, the proposed strategy should comprise solubility enhancement (e.g. 
SMEDDS formulation) and delayed drug release. Although the use of acid-resistant capsules 
was found helpful in protecting the drug against early degradation in GI tract, in silico 
modeling results indicated that pH-controlled drug release system that dissolve above pH 7.0 
or colon delivery system might further improve SV bioavailability. The most important 
clinical benefit is that such an outcome is expected to enable SV dose reduction, and decrease 
the risk of SV-associated adverse effects. The proposed formulation strategy could also be 
applied to other poorly soluble CYP3A4-substrate drugs with similar absorption pattern. 
Further in vivo studies are encouraged to confirm our findings, and support applicability of 
the proposed in vitro/in silico approach to guide formulation strategy.  
In addition, a simplified SV-specific PBPK model developed in this study provided a 
plausible explanation of SV/SVA pharmacokinetics, resulting in reasonable estimates of SV 
plasma exposure after oral administration. Therefore, it can potentially be used to assess the 
influence of formulation factors on drug absorption and disposition when developing SV oral 
dosage forms. However, more complex models that take into account population variability 
in physiological factors and SV pharmacogenetics are needed to enable predictions for 
different patients/population groups. 
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 Table 1. Dissolution test conditions for the experimental setup II 
Row I II III IV V 
Represented GI region stomach duodenum proximal 
jejunum 
distal 
jejunum 
distal 
ileum 
pH value pH 1.2 pH 6.0 pH 6.4 pH 6.9 pH 7.4 
Residence time (min) 15 15 90 60 30 
Hold dip time (s) 30 
Drain time (s) 60 
 
Table 2. Summary of simvastatin/simvastatin acid PBPK model input parameters 
Parameter Value (SV) Value (SVA) 
Molecular weight 418.60 g/mol 436.60 g/mol 
logD (pH 7.0) 4.40
a
 1.88
a 
pKa 13.49
b
 4.31
b 
Human effective permeability, Peff 3.20 x 10
-4
 cm/s
c
 - 
Drug dose 20 mg
d
 - 
Dose volume 200 ml
d
 - 
Solubility (aqueous) 20 µg/ml
e
 - 
Mean precipitation time 900 s
f
 - 
Diffusion coefficient 6.42 x 10
-6
 cm
2
/s
g
 - 
Drug particle density 1.20 g/ml
f
 - 
Effective particle radius 9 µm
h
 - 
Blood/plasma concentration ratio 0.57
i
 0.56
h
 
Unbound percent in plasma 1.34%
h 
5.48%
h 
Intestinal CES Km 237.60 mg/l
j 
- 
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 Intestinal CES Vmax 0.09 mg/s
j
 - 
Hepatic CES Km 85.10 mg/l
j 
- 
Hepatic CES Vmax 0.40 mg/s
j 
- 
CYP3A4 Km 2.01 mg/l
k 
11.06 mg/l
l 
CYP3A4 Vmax 0.57 mg/s
k 
800 mg/s
m 
OATP1B1 Km - 1.10 mg/l
n 
OATP1B1 Vmax - 1 x 10
-5
 mg/s/mg transporter
m 
a
 Taken from [27] 
b
 Taken from [28] 
c
 Calculated from LLC-PK1 cell lines passive permeability [29]; software integrated 
permeability converter 
d
 Taken from [2] 
e
 Experimental value 
f
 GastroPlus™ default 
g
 GastroPlus™ predicted 
h
 Taken from [30] 
i
 Taken from [31] 
j
 Converted from in vitro obtained values [32]; software integrated unit converter 
k
 Converted from in vitro obtained values [33]; software integrated unit converter 
l
 Converted from in vitro obtained value [34]; software integrated unit converter 
m
 Optimized values 
n
 Converted from in vitro obtained value [35]; software integrated unit converter 
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 Table 3. Solubility of simvastatin in various excipients 
Excipient Experimental values 
(mg/ml) 
Range of literature values 
(mg/ml) 
PEG 300 oleic glycerides 53.34 ± 8.89* 30.00-40.96  
[from ref. 8,9] 
Propylene glycol monocaprylate 115.18 ± 7.32 105.00-165.66  
[from ref. 9,11] 
Propylene glycol monolaurate 89.88 ± 12.51 22.00-111.63  
[from ref. 9,11] 
PEG 400 caprylic/capric glycerides 90.64 ± 13.42 76.45-78.00  
[from ref. 8,9] 
Polysorbate 80 73.49 ± 6.02 63.68-117.00  
[from ref. 8,9] 
* mean ± S.D. 
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 Table 4. Composition of the selected SMEDDS  
Components (% w/w) F1 F2 F3 F4 
PEG 300 oleic glycerides 10.0 10.0 10.0 / 
Propylene glycol 
monocaprylate 
/ / / 10.0 
PEG 400 caprylic/capric 
glycerides 
45.0 60.0 67.5 67.5 
Polysorbate 80 45.0 30.0 22.5 22.5 
 
  
Ac
ce
pte
d M
an
us
cri
pt
 Table 5. The average droplet size and polydispersity index of unloaded and simvastatin-
loaded SMEDDS  
 Average droplet size (nm) Polydispersity index 
 after preparation after 3 months after preparation after 3 months 
F1 10.25 ± 0.07* 10.9 8 ± 0.06 0.132 ± 0.007 0.144 ± 0.003 
F2 11.9 0± 0.14 12.11 ± 0.09 0.189 ± 0.006 0.121 ± 0.005 
F3 11.68 ± 0.12 13.73 ± 0.04 0.137 ± 0.016 0.130 ± 0.005 
F4 18.58 ± 0.04 20.88 ± 0.09 0.155 ± 0.005 0.162 ± 0.007 
F1s 13.57 ± 0.06 12.30 ± 0.06 0.181 ± 0.006 0.147 ± 0.006 
F2s 16.03 ± 0.03 16.30 ± 0.06 0.183 ± 0.010 0.160 ± 0.010 
F3s 17.45 ± 0.04 17.91 ± 0.09 0.168 ± 0.005 0.168 ± 0.003 
F4s 46.41 ± 0.17 29.71 ± 0.21 0.286 ± 0.001 0.182 ± 0.011 
* mean ± S.D. 
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 Table 6. Comparison of the predicted and observed simvastatin/simvastatin acid 
pharmacokinetic parameters for 20 mg simvastatin oral dose  
Parameter Predicted Observed* [from ref. 2] 
SV Cmax (ng/ml) 2.36 2.68 ± 1.33 
SV tmax (h) 2.08 2.4 ± 1.65 
SV AUC0→∞ (ng h/ml) 18.62 14.81 ± 7.28 
SVA Cmax (ng/ml) 0.62 0.73 ± 0.36 
SVA tmax (h) 2.96 6.1 ± 1.34 
SVA AUC0→∞ (ng h/ml) 6.19 7.27 ± 3.40 
* mean ± S.D. 
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 Table 7. Predicted simvastatin pharmacokinetic parameters for different formulations  
Parameter Based on 
software 
calculated drug 
dissolution rate 
Based on 
dissolution data 
for F3s filled in 
hard gelatin 
capsules  
(setup I) 
Based on 
dissolution data 
for F3s filled in 
acid-resistant 
capsules  
(setup II) 
Based on 
virtual 
dissolution 
profile (V1) 
Fa
a
 (%) 99.97 100.00 99.99 99.82 
FDp
b
 (%) 19.38 19.26 21.40 28.53 
Fb
c
 (%) 4.66 4.56 5.14 7.20 
Cmax (ng/ml) 2.36 2.94 3.34 4.64 
tmax (h) 2.08 1.20 2.08 3.36 
AUC0→∞ (ng h/ml) 18.62 18.44 20.52 27.95 
a
 Fa - Percent of drug dose absorbed (entered the enterocytes) 
b
 FDp - Percent of drug dose reaching the portal vein 
c
 Fb - Drug bioavailability (as a percent of dose) 
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 Figure captions: 
 
Figure 1. Model scheme of simvastatin and simvastatin acid pharmacokinetics 
Figure 2. Pseudoternary phase diagrams of the systems with propylene glycol monolaurate as 
oil phase and PEG 400 caprylic/capric glycerides/polysorbate 80 in ratios: (A) 1:1, (B) 2:1, 
and (C) 3:1 
Figure 3. Pseudoternary phase diagrams of the systems with propylene glycol monocaprylate 
as oil phase and PEG 400 caprylic/capric glycerides/polysorbate 80 in ratios: (A) 1:1, (B) 2:1, 
and (C) 3:1 
Figure 4. Pseudoternary phase diagrams of the systems with PEG 300 oleic glycerides as oil 
phase and PEG 400 caprylic/capric glycerides/polysorbate 80 in ratios: (A) 1:1, (B) 2:1, and 
(C) 3:1 
Figure 5. Pseudoternary phase diagrams of simvastatin-loaded systems with propylene glycol 
monolaurate as oil phase and PEG 400 caprylic/capric glycerides/polysorbate 80 in ratios: 
(A) 1:1, (B) 2:1, and (C) 3:1 
Figure 6. Pseudoternary phase diagrams of simvastatin-loaded systems with propylene glycol 
monocaprylate as oil phase and PEG 400 caprylic/capric glycerides/polysorbate 80 in ratios: 
(A) 1:1, (B) 2:1, and (C) 3:1 
Figure 7. Pseudoternary phase diagrams of simvastatin-loaded systems with PEG 300 oleic 
glycerides as oil phase and PEG 400 caprylic/capric glycerides/polysorbate 80 in ratios: (A) 
1:1, (B) 2:1, and (C) 3:1 
Figure 8. Comparative dissolution profiles of simvastatin-loaded SMEDDS obtained in a 
basket apparatus (setup I) 
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 Figure 9. Simvastatin dissolution profile from F3s formulation in a reciprocating cylinder 
apparatus (setup II); V1 refer to the virtual dissolution profile illustrating 100% drug release 
in 3 h 
Figure 10. Predicted and in vivo observed [from ref. 2] simvastatin and simvastatin acid 
plasma concentration-time profiles following oral administration of 20 mg simvastatin 
immediate-release tablet 
Figure 11. Predicted simvastatin plasma concentration-time profiles for F3s formulation filled 
in conventional and acid-resistant hard gelatine capsules, along with the profile predicted 
based on virtual dissolution V1 
Figure 12. Predicted compartmental absorption of simvastatin following oral administration 
of different formulations 
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